Targeted Therapies in Oncology
Release Date: March 3, 2008
Expiration Date: March 3, 2009
Davide Melisi,MD; David J. McConkey,Phd
Traditional cytotoxic chemotherapy is believed to kill cancer cells by activation of apoptosis, often as a result of DNA-damage signaling. However, these chemotherapeutic agents also act on normal cells, resulting in toxicities such as myelosuppression. Recent approaches have focused on activating apoptotic pathways specifically in malignant cells. Apoptotic signaling can be initiated by tumor necrosis factorñrelated apoptosis-inducing ligand (TRAIL), which binds to TRAIL receptors 1 and 2; agonistic antibodies to the TRAIL receptors are also in development. Other novel targets include cyclin-dependent kinases, which regulate progression through the cell cycle, Aurora kinases, which ensure proper chromosome separation during mitosis, and poly(ADP-ribose) polymerase-1, which is involved in DNA repair. Agents targeting these molecules are in early-phase clinical trials.
The purpose of this activity is to update physicians on novel targets for anticancer approaches including death receptors, cell-cycle proteins, and DNA repair enzymes.